A deal was reached to provide continued access to crucial drugs treating cystic fibrosis, ensuring availability for all eligible patients in the UK.
Negotiations with NICE led to the approval of modulator drugs despite initial concerns over costs, applying a unique approach to evaluating non-cancer medicines.
[
Collection
]
[
|
...
]